4780-14-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Methoxy-2-Methyl-pyran-4-one is used as a reagent for the synthesis of Staphylococcus antibacterials. It plays a crucial role in the development of new drugs to combat Staphylococcus infections, which are common and can sometimes be resistant to conventional antibiotics.
In the pharmaceutical industry, 3-Methoxy-2-Methyl-pyran-4-one is utilized in the synthesis process to create novel antibacterial agents that can effectively target and eliminate Staphylococcus bacteria, contributing to the development of more effective treatments for various infections caused by this type of bacteria.

InChI:InChI=1/C7H8O3/c1-5-7(9-2)6(8)3-4-10-5/h3-4H,1-2H3

Upstream product

• 118-71-8 Maltol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 61049-69-2 3-O-benzylmaltol 
• 75-52-5 nitromethane 
• 82209-15-2 C₈H₁₁O₃⁽¹⁺⁾*FO₃S^(1-) 
• 6814-64-8 methylenedimethyl sulfurane 

Downstream Products

• 54312-21-9 N-(p-tolyl)-3-methoxy-2-methyl-4-pyridone 
• 127394-38-1 3-Methoxy-1-(4-methoxy-phenyl)-2-methyl-1H-pyridin-4-one 
• 127394-39-2 N-(4-nitrophenyl)-3-methoxy-2-methyl-4-pyridone 
• 54312-20-8 3-Methoxy-2-methyl-1-phenyl-1H-pyridin-4-one 
• 76015-11-7 3-methoxy-2-methylpyridin-4(1H)-one 
• 64-18-6 formic acid 
• 5878-19-3 Methoxyacetone 
• 64-19-7 acetic acid 
• 1436415-54-1 methyl 2-{6-[1-((tert-butyldimethylsilyl)oxy)propyl]-5-methoxy-4-oxo-4H-pyran-3-carbonyl}-3,5-dimethoxybenzoate 
• 127394-43-8 3-Hydroxymethyl-2-methyl-1-(4-nitro-phenyl)-1H-pyridin-4-one 
• 127394-42-7 3-Hydroxymethyl-1-(4-methoxy-phenyl)-2-methyl-1H-pyridin-4-one 
• 127394-41-6 N-(p-tolyl)-3-hydroxymethyl-2-methyl-4-pyridone 
• 76349-10-5 2-methyl-3-<<(methylamino)carbonyl>oxy>-4(1H)-pyridone 

Relevant academic research and scientific papers

'Unconventional' coordination chemistry by metal chelating fragments in a metalloprotein active site

The binding of three closely related chelators: 5-hydroxy-2-methyl-4H- pyran-4-thione (allothiomaltol, ATM), 3-hydroxy-2-methyl-4H-pyran-4-thione (thiomaltol, TM), and 3-hydroxy-4H-pyran-4-thione (thiopyromeconic acid, TPMA) to the active site of human ca

Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity

A series of (3-hydroxypyridin-4-one)-coumarin hybrids were developed and investigated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through the incorporation of iron-chelating and monoamine oxidase B (MAO-B) inhibition. This combination endowed the hybrids with good capacity to inhibit MAO-B as well as excellent iron-chelating effects. The pFe3+ values of the compounds were ranging from 16.91 to 20.16, comparable to more potent than the reference drug deferiprone (DFP). Among them, compound 18d exhibited the most promising activity against MAO-B, with an IC50 value of 87.9 nM. Moreover, compound 18d exerted favorable antioxidant activity, significantly reversed the amyloid-β1-42 (Aβ1-42) induced PC12 cell damage. More importantly, 18d remarkably ameliorated the cognitive dysfunction in a scopolamine-induced mice AD model. In brief, a series of hybrids with potential anti-AD effect were successfully obtained, indicating that the design of iron chelators with MAO-B inhibitory and antioxidant activities is an attractive strategy against AD progression.

Coumarin hybrid pyridinone amide derivative with potential anti-AD activity and preparation method and application of derivative

The invention discloses a coumarin hybrid pyridinone amide derivative and a preparation method and application thereof. The coumarin hybrid pyridinone amide derivative and pharmacologically acceptablesalt thereof are shown in the formula (I) and the formula (II), and the derivative can be used for preparing drugs for resisting the Alzheimer's disease, the Parkinson's disease or treating other diseases or symptoms by suppressing monoamine oxidase, chelating metallic iron ions, resisting A and resisting oxidation.

Coumarin heterozygous pyridone compounds having iron chelation and monoamine oxidase B inhibitory activity as well as preparation and application of compounds

The invention discloses coumarin/pyridone heterozygous derivatives represented by a formula (I) shown in the description or a pharmaceutically-acceptable salt of the derivatives. The preparation method of the coumarin/pyridone heterozygous derivatives comprises the following steps: one pyridone derivative represented by a formula 3 shown in the description is obtained by a series of synthesis by using one hydroxypyrone with different substituent groups represented by a formula 1 shown in the description as a raw material; and a compound represented by a formula 4 shown in the description is subjected to a condensation reaction to obtain a compound represented by a formula 5 shown in the description, one-step bromination is performed to obtain a compound represented by a formula 6 shown inthe description, the compound represented by the formula 6 and the pyridone derivative represented by the formula 3 are subjected to a one-step nucleophilic substitution reaction to obtain a compoundrepresented by a formula 7 shown in the description, and finally an alkyl protecting group in a pyridone structure is removed to obtain one target compound represented by the formula (I). The compounds provided by the invention are a novel series of single-molecular multi-target series drugs, and have iron chelation, targeted MAO-B inhibitory activity, antioxidant activity, unique advantages for an Alzheimer disease with complicated pathogenesis, a clear mechanism of action and excellent activity.

Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease

A series of hybrids of hydroxypyridinone and coumarin were rationally designed, synthesized and biologically evaluated for their iron ion chelating and MAO-B inhibitory activities. Most of the compounds displayed excellent iron ion chelating effects and moderate to good anti-MAO-B activities. Compound 27a exhibited the most potent activity against MAO-B, with an IC50 value of 14.7 nM. Importantly, 27a showed good U251 cell protective effect and significantly ameliorated the cognitive dysfunction of scopolamine-induced AD mice. Moreover, molecular docking was performed to elucidate the probable ligand-receptor interaction, and the structure-activity relationships were also summarized.

Synthetic method for amino-containing hydroxypyridone compound

The invention discloses a synthetic method for an amino-containing 3-hydroxypyridine-4-ketone iron chelating agent as shown in a formula (III) which is described in the specification. The synthetic method comprises the following steps: with methyl-protected azido hydroxypyridone as shown in a formula (I) which is described in the specification as a raw material, allowing the methyl-protected azido-hydroxypyridine to generate reduction and demethylation reactions under the protection of boron tribromide as shown in a formula (II) which is described in the specification, a solvent A and gas B, after completion of the reactions, carrying out quenching with a solvent C, and carrying out post-treatment so as to obtain the amino-containing 3-hydroxypyridine-4-ketone compound as shown in the formula (III). Compared with a conventional method, the synthetic method provided by the invention adopts a boron tribromide reagent with mild reaction conditions, avoids the use of a metal catalyst, andhas simple and convenient operation and high reaction yield.

Macromolecular iron-chelators via RAFT-polymerization for the inhibition of methicillin-resistant Staphylococcus aureus growth

A series of linear poly (glycidyl methacrylate) (PGMA) polymers were synthesized via RAFT polymerization and conjugated with amine-containing 3-hydroxypyridin-4-ones (HPOs) to generate a panel of HPO-containing materials with controlled structures and spe

Total syntheses and biological evaluation of 3-O-methylfunicone and its derivatives prepared by TMPZnCl·LiCl-mediated halogenation and carbonylative stille cross-coupling

The total syntheses of the natural product 3-O-methylfunicone (1), a member of the funicone class of compounds, and its derivatives is reported. The key reactions in the construction of the biaryl ketone core are a regioselective TMPZnCl·LiCl halogenation and a carbonylative Stille cross-coupling reaction. In addition, the inhibitory activities of the funicones against Y-family DNA polymerase κ (pol κ) and polymerase η (pol η) were determined. We found that 1 and 12 exhibit inhibitory activity against pol η and 1 also against pol κ. The total syntheses of the natural product 3-O-methylfunicone and its derivatives has been accomplished. The key reactions are TMPZnCl·LiCl-mediated iodination and a carbonylative Stille cross-coupling reaction. In addition, the inhibitory effect of the synthesized compounds have been evaluated against Y-family DNA polymerases κ and η by primer extension experiments. Copyright

Synthesis, antiplasmodial activity, and β-hematin inhibition of hydroxypyridone-chloroquine hybrids

A series of noncytotoxic 4-aminoquinoline-3-hydroxypyridin-4-one hybrids were synthesized on the basis of a synergistic in vitro combination of a precursor N-alkyl-3-hydroxypyridin-4-one with chloroquine (CQ) and tested in vitro against CQ resistant (K1 and W2) and sensitive (3D7) strains of Plasmodium falciparum. In vitro antiplasmodial activity of the precursors was negated by blocking the chelator moiety via complexation with gallium(III) or benzyl protection. None of the precursors inhibited β-hematin formation. Most hybrids were more potent inhibitors of β-hematin formation than CQ, and a correlation between antiplasmodial activity and inhibition of β-hematin formation was observed. Potent hybrids against K1, 3D7, and W2, respectively, were 8c (0.13, 0.004, and 0.1 μM); 8d (0.08, 0.01, and 0.02 μM); and 7g (0.07, 0.03, and 0.08 μM).

Prediction of 3-hydroxypyridin-4-one (HPO) hydroxyl pKa values

As an aid in optimising the design of 3-hydroxypyridin-4-ones (HPOs) intended for use as therapeutic Fe3+ chelating agents, various quantum mechanical (QM) and semi-empirical (QSAR) methods have been explored for predicting the pKa values of the hydroxyl groups in these compounds. Using a training set of 15 HPOs with known hydroxyl pKa values, reliable predictions are shown to be obtained with QM calculations using the B3LYP/6-31+G(d)/CPCM model chemistry (with Pauling radii, and water as solvent). With this methodology, the observed hydroxyl pKa values for the training set compound are closely matched by the predicted pKa values, with the correlation between the observed and predicted values giving r2 = 0.98. Predictions subsequently made by this method for a test set of 48 HPOs of known hydroxyl pKa values (11 of which were determined experimentally in this study), gave predicted pKa values accurate to within ±0.2 log units. In order to further investigate the predictive power of the method, two novel HPOs were synthesised and their hydroxyl pKa values were determined experimentally. Comparison of these predicted pKa values against the measured values gave absolute deviations of 0.13 (10.18 vs. 10.31) and 0.43 (5.58 vs. 5.15).